News & Events

Update on All things Huntington's Australia Well, the merger implementation is in full swing and just about everyone is getting involved in some way, shape or form. Firstly and perhaps most importantly, all staff are in the process of having...

Following your request to receive timely updates about our Huntington’s disease (HD) research efforts, this letter provides information about the opening of the GENERATION HD2 study and a summary of our scientific collaboration efforts in 2022.

We're delighted to share that Huntington's Australia (HA) have appointed a CEO. Welcome Lenni Duffield! Further information from the Chair of HA, Chris Glasson, is available here.

I am writing to inform you that the members who attended recent AGMs of the five Huntington’s State Associations – SA&NT, WA, Tasmania, NSW/ACT and Queensland – have agreed to merge.

Sage Therapeutics are pleased to share an important update on the clinical development program for Sage Therapeutics Inc.’s investigational drug, SAGE-718.

Huntington's WA will once again be part of #Light It Up 4 HD, an initiative that started in Canada some 6 years ago. #Light It Up 4 HD has become a global success story with a vast number of iconic buildings lighting up in blue and/or purple in support...